FOXO1 and esophageal squamous cell carcinoma: In addition, activation of FOXO1 in esophageal squamous cell carcinoma upregulates cancer-associated fibroblasts and promotes the secretion of TGF-β1, thereby inducing cisplatin and paclitaxel resistance in esophageal squamous cell carcinoma cells (68).